BioInvent International AB (publ)
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an a… Read more
BioInvent International AB (publ) (BOVNF) - Total Assets
Latest total assets as of September 2025: $780.41 Million USD
Based on the latest financial reports, BioInvent International AB (publ) (BOVNF) holds total assets worth $780.41 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BioInvent International AB (publ) - Total Assets Trend (2002–2024)
This chart illustrates how BioInvent International AB (publ)’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BioInvent International AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2024)
BioInvent International AB (publ)'s total assets of $780.41 Million consist of 95.4% current assets and 4.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 44.0% |
| Accounts Receivable | $8.27 Million | 0.8% |
| Inventory | $10.97 Million | 1.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2002–2024)
This chart illustrates how BioInvent International AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioInvent International AB (publ)'s current assets represent 95.4% of total assets in 2024, an increase from 85.8% in 2002.
- Cash Position: Cash and equivalents constituted 44.0% of total assets in 2024, down from 77.0% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2002.
- Asset Diversification: The largest asset category is inventory at 1.1% of total assets.
BioInvent International AB (publ) Competitors by Total Assets
Key competitors of BioInvent International AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
BioInvent International AB (publ) - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - BioInvent International AB (publ) generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - BioInvent International AB (publ) is currently not profitable relative to its asset base.
BioInvent International AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.40 | 13.29 | 14.45 |
| Quick Ratio | 7.31 | 13.16 | 14.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $643.16 Million | $ 934.92 Million | $ 719.53 Million |
BioInvent International AB (publ) - Advanced Valuation Insights
This section examines the relationship between BioInvent International AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.52 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | -29.3% |
| Total Assets | $989.24 Million |
| Market Capitalization | $144.95 Million USD |
Valuation Analysis
Below Book Valuation: The market values BioInvent International AB (publ)'s assets below their book value (0.15 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: BioInvent International AB (publ)'s assets decreased by 29.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BioInvent International AB (publ) (2002–2024)
The table below shows the annual total assets of BioInvent International AB (publ) from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $989.24 Million | -29.35% |
| 2023-12-31 | $1.40 Billion | -18.22% |
| 2022-12-31 | $1.71 Billion | +18.30% |
| 2021-12-31 | $1.45 Billion | +80.32% |
| 2020-12-31 | $802.64 Million | +254.98% |
| 2019-12-31 | $226.11 Million | +87.80% |
| 2018-12-31 | $120.40 Million | -29.20% |
| 2017-12-31 | $170.05 Million | -38.46% |
| 2016-12-31 | $276.30 Million | +407.46% |
| 2015-12-31 | $54.45 Million | -26.53% |
| 2014-12-31 | $74.11 Million | -9.00% |
| 2013-12-31 | $81.44 Million | -30.12% |
| 2012-12-31 | $116.54 Million | -43.36% |
| 2011-12-31 | $205.76 Million | +49.07% |
| 2010-12-31 | $138.03 Million | +9.33% |
| 2009-12-31 | $126.25 Million | -57.27% |
| 2008-12-31 | $295.43 Million | +9.01% |
| 2007-12-31 | $271.00 Million | +82.70% |
| 2006-12-31 | $148.33 Million | -44.31% |
| 2005-12-31 | $266.34 Million | +11.72% |
| 2004-12-31 | $238.41 Million | -30.53% |
| 2003-12-31 | $343.19 Million | -23.12% |
| 2002-12-31 | $446.41 Million | -- |